Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 3 Glioblastoma 2 Vulvar Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Melanoma 1 Locally Advanced Rectal Carcinoma 1 Hypoxia 1 Gliosarcoma 1 Glioma 1 Genetic Diseases, Inborn 1 Esophageal Neoplasms 1 Circulating Tumor DNA 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

Docetaxel 292 Prednisone 240 enzalutamide 193 Leuprolide 185 Radiotherapy 179 Abiraterone Acetate 169 Magnetic Resonance Spectroscopy 163 bicalutamide 141 Goserelin 138 Androgen Antagonists 121 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 108 Radiosurgery 108 apalutamide 92 gallium 68 PSMA-11 81 abiraterone 81 Specimen Handling 73 darolutamide 65 Surveys and Questionnaires 64 Gonadotropin-Releasing Hormone 63 Triptorelin Pamoate 58 Radiation 57 Biopsy 57 Brachytherapy 54 cabazitaxel 52 Standard of Care 51 Radiotherapy, Intensity-Modulated 51 Zoledronic Acid 50 pembrolizumab 49 luprolide acetate gel depot 49 Flutamide 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostatic Neoplasms × Circulating Tumor DNA × Clear all

NCT05702619 2023-01-27

HYPROGEN

The Christie NHS Foundation Trust

Hypoxia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡